| __timestamp | Gilead Sciences, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3788000000 | 12665000 |
| Thursday, January 1, 2015 | 4006000000 | 20202000 |
| Friday, January 1, 2016 | 4261000000 | 32407000 |
| Sunday, January 1, 2017 | 4371000000 | 35219000 |
| Monday, January 1, 2018 | 4853000000 | 36386000 |
| Tuesday, January 1, 2019 | 4675000000 | 43081000 |
| Wednesday, January 1, 2020 | 4572000000 | 39330000 |
| Friday, January 1, 2021 | 6601000000 | 43283000 |
| Saturday, January 1, 2022 | 5657000000 | 48316000 |
| Sunday, January 1, 2023 | 6498000000 | 54634000 |
| Monday, January 1, 2024 | 28675800000 |
In pursuit of knowledge
In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost dynamics is crucial. Gilead Sciences, Inc. and MiMedx Group, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Gilead's cost of revenue surged by approximately 72%, peaking in 2021 with a notable 42% increase from the previous year. This reflects Gilead's aggressive expansion and investment in research and development. Meanwhile, MiMedx Group, Inc. experienced a more modest growth of around 331% over the same period, highlighting its steady yet impactful market presence. The year 2023 saw MiMedx's cost of revenue reach its highest, indicating a potential strategic pivot or increased production. These trends underscore the diverse strategies employed by companies in the sector, offering valuable insights for investors and industry analysts alike.
Analyzing Cost of Revenue: Amgen Inc. and MiMedx Group, Inc.
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Corcept Therapeutics Incorporated
Cost of Revenue Trends: Gilead Sciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
GSK plc vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and MiMedx Group, Inc.'s Expenses
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and MiMedx Group, Inc.'s Expenses
Cost of Revenue Trends: Grifols, S.A. vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: ACADIA Pharmaceuticals Inc. vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: MorphoSys AG vs MiMedx Group, Inc.
Cost Insights: Breaking Down Vericel Corporation and MiMedx Group, Inc.'s Expenses
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.